In Taiwan, drug packaging must comply with TFDA regulations to ensure safety and proper usage. Requirements include clear labeling with dosage, ingredients, storage instructions, and expiration dates, all provided in Chinese. Packaging must also meet tamper-evident standards and ensure product stability. TFDA... Read More
The TFDA ensures drug quality in Taiwan through Good Manufacturing Practice (GMP) compliance, requiring robust quality control systems and conducting on-site inspections of production facilities. It also performs post-market surveillance and periodic testing to verify that products consistently meet regulatory standards throughout... Read More
Local drug registration in Taiwan refers to the approval process for domestically produced drugs, focusing on local regulations and clinical trials. Multinational drug registration involves approval for foreign-manufactured drugs, requiring additional steps like overseas clinical data, documentation, and adherence to international and... Read More
In Taiwan, drugs for rare diseases are registered through accelerated pathways offered by the TFDA. These orphan drugs benefit from priority review to expedite approval, addressing unmet medical needs. Applicants must submit clinical data, GMP compliance documents, and risk management plans. Post-market... Read More
In Taiwan’s drug registration process, the TFDA evaluates efficacy through clinical trial data that demonstrates the drug’s ability to produce the desired therapeutic effect. The review includes Phase II and Phase III trial results, focusing on measurable outcomes. If foreign data is... Read More
Toxicology reports are essential in Taiwan’s drug registration to assess a drug’s safety profile before clinical trials and market approval. These reports evaluate potential toxic effects, including acute and chronic toxicity, carcinogenicity, and reproductive toxicity. The TFDA uses this data to ensure... Read More
In Taiwan, clinical trials for drug registration follow international standards. Phase I assesses safety and dosage in small groups. Phase II evaluates efficacy and side effects in larger groups. Phase III involves large-scale testing to confirm effectiveness and monitor adverse reactions. Data... Read More
To register a drug in Taiwan, pharmacology requirements include detailed data on pharmacodynamics, pharmacokinetics, toxicity, and clinical trial results. The Taiwan Food and Drug Administration (TFDA) mandates that manufacturers provide evidence of safety, efficacy, and quality, following guidelines aligned with international standards... Read More
To register an innovative drug in Taiwan, applicants must submit a New Drug Application (NDA) with clinical trial data proving safety, efficacy, and quality, along with Good Manufacturing Practice (GMP) compliance documentation. The TFDA conducts thorough reviews, with the possibility of accelerated... Read More
Pharmacovigilance is crucial in Taiwan’s drug registration to ensure ongoing safety monitoring after market approval. It involves tracking adverse events, submitting Periodic Safety Update Reports (PSURs), and updating drug labels as new risks emerge. The TFDA’s pharmacovigilance system ensures public health protection... Read More